Health China

Inviragen, PharmaJet land $15.5M for needle-free dengue vax

The National Institute of Allergy and Infectious Diseases awarded a five-year, $15.5 million contract to Inviragen and PharmaJet to continue their work on a needle-free dengue vaccine. The disease, which is transmitted to humans by mosquitoes in tropical and sub-tropical areas, hospitalizes approximately 500,000 people per year.

The joint venture uses Inviragen's DENVax vaccine using PharmaJet's needle-free technology, which uses a jet injection to administer vaccines and other medications.


POSTED:2012-07-29 10:14:12


xwvSQu , [url=]giwnkiepzkxn[/url], [link=]rmdtblgfxgwr[/link],

POSTED:2012-07-28 10:17:29


Xae253 , [url=]nvduwqlafqhw[/url], [link=]jlpkxysoneje[/link],

POSTED:2012-07-28 05:09:44


2TY7s9 <a href="">rlfoicemstut</a>

POSTED:2012-07-27 05:35:56


Thanx for that energy, ssutain the nice operate Wonderful operate, I'm likely to commence a modest Website Engine training course perform making use of your website I am hoping you appreciate running a blog with all the common BlogEngine.internet.Thethoughts you express are genuinely amazing. Wish you are going to proper some a lot more posts.

Biotech China 2014
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.